"Treatment"

Vocal cord cancer often leads to hoarseness, which is a common symptom of many diseases and can be easily overlooked by patients.

Speaking of halitosis, my mind immediately flashed a scene like this: the doorbell rang, and he was anxious to wait for his girlfriend to come. He hurriedly told the parrot a few words. Unexpectedly, the parrot was stunned by his halitosis, fell down and shouted, "You have bad breath! You have bad breath!" Funny aside, you may ask: What causes halitosis? What's the best way to eliminate bad breath?

Every disease has a cause, and we are all sick because of various factors. Understanding the causes of diseases can help us to prevent them, which will help our health a lot.

There are many ways to treat prostate cancer and radiation therapy is a common treatment for prostate cancer, but many prostate cancer patients want to know what the side effects of radiation therapy are.

Bladder cancer is one of the common diseases nowadays. The incidence of cancer is still very high and many people are affected by cancer, so some bladder cancer patients want to know if the disease is hereditary

Pfizer's new treatment, Elranatamab, has received Breakthrough Therapy designation from the FDA for the treatment of patients with relapsed or refractory multiple myeloma. Data from the trial showed a patient efficacy rate of 61.0% and that once the therapy is effective, efficacy is maintained for more than six months in over 90% of patients!

There are many treatment options for bladder cancer, but surgery is a frequently used treatment, and some bladder cancer patients want to know about post-operative diet

If you are suffering from itchy hair and hair loss, it is important to understand the causes of itchy hair and hair loss so that you can get to the root of the problem. For example, some people only have mild hair loss, which can be relieved after certain adjustments, while others have both itchy symptoms and hair loss symptoms that are more pronounced, so it is also important to pay attention to the right treatment

Data from a trial show that adding the new drug Eganelisib to standard treatment significantly improves the length of survival for patients with triple-negative breast cancer whose disease remains unexacerbated. Patients benefited regardless of their PD-L1 status.

Recent findings show that the use of cutting-edge immune checkpoint inhibitor therapy (referred to as immunotherapy in this article) has increased rapidly over the past decade in the population of patients with advanced non-small cell lung cancer (NSCLC), but the survival benefit is more pronounced in younger people than in older people, who have limited survival benefit with this therapy.